Full-Time

Senior Director Clinical & Translational Research

Clinical and Translational Research

Updated on 7/16/2026

Omada Health

Omada Health

501-1,000 employees

Virtual care provider delivering chronic-condition management

Compensation Overview

$243.8k - $304.8k/yr

+ Bonus + Equity Grants

Remote in USA

Remote

Category
Biology & Biotech (1)

Get referred to Omada Health

Find people who can refer or advise you

Requirements
  • Advanced degree (Ph.D., Pharm.D., or M.D.) in health services research, psychology, public health, or related fields
  • Minimum of 10 years of relevant clinical research experience
  • Deep expertise in health economics and outcomes research (HEOR), including hands-on and/or leadership experience with healthcare claims analysis, cost and utilization modeling, and total cost of care analyses for Medicare Advantage and commercial employer populations
  • Familiarity with quality measurement frameworks such as HEDIS and Medicare Advantage Star Ratings, including experience using these measures to evaluate and communicate program impact
  • Demonstrated track record of designing and leading studies, including clinical trials, observational studies, economic evaluations, and patient-reported outcomes research
  • Strong leadership and team management skills, with the ability to inspire and motivate cross-functional teams towards common goals
  • Exceptionally collaborative and adaptable, with the ability to forge strong relationships across multiple functions and domains and to flex to meet business priorities
  • Excellent communication and presentation skills, with the ability to effectively convey complex scientific concepts to diverse audiences
  • Strategic thinker with a results-oriented mindset and the ability to thrive in a fast-paced, entrepreneurial environment
  • Ability and readiness for quick growth opportunities. This is a fast track position with potential for VP level responsibilities within 1 year
Responsibilities
  • Design, oversee, and execute clinical research studies and health economics research studies and analyses, including randomized controlled trials, observational cohort studies, economic models, healthcare claims analyses, and real-world evidence (RWE), evaluating the clinical and economic outcomes and highlighting the value associated with Omada’s digital health programs.
  • Lead the development and interpretation of health economics and outcomes research (HEOR), including cost-effectiveness, budget impact, and total cost of care analyses that clearly articulate value to Medicare Advantage plans, commercial employers, and provider partners.
  • Lead and mentor a team of PhD-level scientists (4) and project manager, providing guidance, coaching, and professional development opportunities.
  • Manage external research vendors, consultants, and partners.
  • Ensure compliance with regulatory requirements, ethical standards, and industry best practices in all research activities and publications.
  • Publish research findings in peer-reviewed journals and white papers.
  • Author Thought Leadership pieces to represent the company’s position on relevant clinical topics.
  • Collaborate closely with Clinical Strategy and Commercial teams, including Sales and Marketing, to develop compelling and evidence-based value stories and to translate research findings to Commercial-facing assets.
  • Collaborate with Clinical Innovation (including Product, Care Delivery, and Data) in the development of personalized program experiments and quality improvement projects in service of improving member engagement and outcomes.
  • Ensure sound and ethical scientific practices are followed, clinical rigor is maintained, and experiments are grounded in evidence-based behavioral science with high likelihood of making a meaningful impact on engagement and clinical outcomes, quality metrics and economic value.
  • Seek broad input from cross-functional teams (e.g., Marketing/Sales, Clinical, Care Team) to determine business impactful and clinically meaningful metrics for key program development pilots. Generate and oversee the Evaluation Plans for the pilots to ensure they are designed to meet business impactful metrics.
  • Collaborate with the Subject Matter Experts (SME) for Behavior Change and Behavioral Health with R&D to inform program personalization and clinical impact, including in the development of meaningful interventions for programmatic pilots.
  • Serve as a Subject Matter Expert (SME) for Clinical Outcomes and Health Economics with Commercial Teams, including internal consultation as well as customer-facing meetings with consultants, actuaries and data-savvy customers.
Desired Qualifications
  • Ability and readiness for quick growth opportunities. This is a fast track position with potential for VP level responsibilities within 1 year.

Omada Health provides virtual-first, integrated care with clinically supported programs for chronic conditions. Its online programs use evidence-based medical protocols combined with behavior science, delivered with the help of health coaches and clinical specialists to help people achieve long-term health improvements. The company serves over 1,600 enterprise customers and partners with major employers, health plans, and health systems, delivering personalized interventions for diabetes prevention, weight management, diabetes, hypertension, musculoskeletal issues, and behavioral health. Its goal is to make sustained healthy behavior possible by offering accessible, scalable care that reduces healthcare costs and improves ROI for partners.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2011

Get referred to Omada Health

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Revenue grew 53% in 2025, with Q4 2025 profit of $5.1 million versus an $8.2 million loss in 2024.
  • GLP-1 users on Omada achieve 18.4% average weight loss and 67% one-year medication persistence versus real-world benchmarks.
  • GLP-1 Flex Care launches later in 2026, targeting 55% of large employers without GLP-1 coverage to expand access.

What critics are saying

  • Cigna affiliates represent 66% of Q1 2026 revenue; any contract reduction could instantly collapse Omada's cash flow.
  • Teladoc's multi-condition bundling erodes Omada's employer moat as 75% of new customers select multiple programs favoring integrated suites.
  • Virta Health's direct-to-employer GLP-1 prescribing bypasses Omada's PBM gateway, undermining its 80% commercial prescription coverage advantage.

What makes Omada Health unique

  • Omada is the largest CDC-recognized provider of the National Diabetes Prevention Program.
  • It uniquely combines human-led care teams with AI and connected devices for between-visit cardiometabolic care.
  • Omada offers integrated GLP-1 prescribing plus lifestyle support across PBM, direct-to-employer, and cash-pay channels.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote first - Join Omada from anywhere in the US. No matter where you’re located, we budget for travel so your team can come together.

Flexible vacation - Invest in yourself and your loved ones with flexible time away and monthly wellness days.

Parental leave - We support all new parents with competitive leave policies and flexible schedules upon return.

Omada program - Join our best-in-class program to reach your health goals, and invite a loved one to join you too.

Meeting-free days - Every Wednesday afternoon, we observe company-wide focus time with nothing on the calendar.

Resources to thrive - Invest in inclusion with resource groups, equity training, and a cross-functional team dedicated to belonging.

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
U.S. Small Business Administration
Apr 30th, 2026
Award | SBIR

DESCRIPTION (provided by applicant): Approximately 32% of Medicare spending is attributed to diabetic populations, and the prevalence of diabetes is growing at an alarming rate. Approximately 79 million Americans have prediabetes. The landmark 2002 Diabetes Prevention Program (DPP) demonstrated that lifestyle modification is a successful approach to preventing diabetes. The DPP lifestyle changes reduced the risk of developing diabetes in patients with prediabetes by 58% at 3 years following the intervention. The DPP involved a curriculum of 16 lessons delivered one-on-one over 6 months and a follow-up maintenance program over the remaining year. While the DPP lifestyle modification program was overwhelmingly successful, its wide-spread implementation necessitates the development of cost-effective delivery channels. While the NIH and UnitedHealth Group have invested in a pilot program to adapt the curriculum to a group format delivered at the YMCA, alternatives that are scalable and accessible are necessary tomake the DPP available across a broader segment of society. Omada Health is developing an interactive DPP curriculum from the recently released CDC DPP curriculum; this curriculum is designed to be delivered on a user-friendly web-based platform that Omada Health has built for virtual small groups. The goal of this proposal is to enhance the basic DPP curriculum with interactive and tailored components to motivate and engage users, increase participation, and improve health outcomes. Research into specificelements of online behavior interventions has demonstrated that interactive features, such as personalized email contact and bulletin board participation, may improve user outcomes. Upon completion of these specific aims, Omada Health will conduct large pilot studies and commercialize the web-based DPP curriculum and platform through strategic partnerships. Omada Health's online distribution model makes this diabetes prevention program ideal for rapid, nationwide expansion. Not only is this solution scalable, but it is more convenient and accessible for individuals with limited time and does not depend on access to a particular geographic location or vendor. Thus, Omada Health's interactive DPP is an ideal alternative to the pioneering YMCA-based DPP and has the potential to revolutionize the delivery of diabetes prevention programs. Omada Health has assembled an impressive team of collaborators to support and enhance their efforts, including: Martha Funnell, MS, a prominent diabetes educatory and past-chairof the National Diabetes Education Program; Anne Peters, MD, a renowned dialectologist and head of the USC Clinical Diabetes Program; Mark Berman, MD, an internal medicine physician with a focus on lifestyle medicine; Chip Heath, PhD, Professor of Organizational Behavior at Stanford University, an expert in behavior modification; and Willem Van Lancker, a Lead User Experience Designer at Google. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Preventing diabetes in the estimated 79 million Americans with prediabetes is a public health priority. Lifestyle modification programs that focus on physica activity and healthy diet have been shown to be highly effective in preventing diabetes. The goal of this project is to develop interactive componentssuch as games, group response fields, quizzes, and videos to improve an online, virtual group diabetes prevention program to motivate users towards better health and to prevent diabetes.

Yahoo Finance
Mar 14th, 2026
Omada Health: Digital healthcare stock at $14 trades at 3x sales with 53% revenue growth

Omada Health, a digital healthcare company focused on chronic condition management, went public in June 2025 and currently has an $800 million market capitalisation. The company's mobile app provides between-visit guidance for patients with conditions like diabetes, hypertension and obesity, offering access to health coaches, specialists and tracking tools. Omada has achieved 90% customer retention and 50% member engagement after two years. The company reports that GLP-1 users on its platform experience 28% more weight loss than those using medication alone, whilst members who discontinued GLP-1 but continued with Omada regained only 1% of body weight versus 11% for non-users. The company grew sales by 53% in 2025, with profit margins rising from negative 16% to 6% in the fourth quarter. The stock trades at three times sales.

Yahoo Finance
Mar 6th, 2026
Omada Health Q4 earnings soar 420% above estimates to $0.13 per share

Omada Health reported Q4 2025 revenue of $75.85 million, flat year-over-year but beating the consensus estimate of $73 million by 3.9%. The digital health company posted earnings per share of $0.13, compared to $0 in the year-ago quarter, significantly exceeding the $0.03 analyst estimate. The company's total membership reached 886,000, surpassing the analyst average estimate of 860,009. Services revenue came in at $71.65 million, beating the $64.53 million estimate, whilst hardware revenue of $4.2 million fell short of the $4.96 million projection. Omada Health shares have returned 0.1% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.

TechTarget
Mar 6th, 2026
Omada Health reports Q4 profit, offers new GLP-1 cash-pay option

Omada Health reports Q4 profit, offers new GLP-1 cash-pay option. The digital health provider reported a profitable fourth quarter with strong revenue and membership growth in 2025, and a new employer-focused cash-pay option for GLP-1s. Published: 06 Mar 2026 Omada Health, a digital health provider focused on chronic disease, announced its first profitable quarter and a new cash-pay option for GLP-1 medications on March 5. The company shared its fiscal year 2025 financial results, reporting full-year revenue of $260 million, up 53% from $169.8 million in 2024. Its revenue for the fourth quarter (Q4) of 2025 increased by 58%, from $47.9 million in Q4 2024 to $75.8 million in Q4 2025. Additionally, the company turned a profit in Q4 2025, reporting net income of $5.1 million, compared with a net loss of $8.2 million in Q4 2024. It reduced its year-over-year net losses, ending 2025 with a net loss of $12.7 million, down from $47 million in 2024. Omada Health, which went public in June 2025, ended the year with 886,000, up 55% year over year. The company noted that it is supporting 150,000 members on GLP-1s, compared with more than 50,000 at the end of 2024. Company leaders highlighted the adoption of GLP-1s as a critical driver of growth. During an earnings call, Omada CFO Steven Cook stated that the "broad industry focus on cardiometabolic conditions, deeper penetration of multi-condition customers, strong adoption of our GLP-1 programs and more effective enrollment campaigns" were the primary growth drivers for the company in 2025. The company is making further inroads into the GLP-1 market. In addition to its GLP-1 Enhanced Care Track, which offers members on GLP-1 medications personalized access to care teams, nutrition support and more, and GLP-1 virtual prescribing capability, Omada Health has launched GLP-1 Flex Care. The new offering will allow members to purchase their GLP-1 medications on a cash-pay basis. The members will also receive medication management, nutrition and activity counseling and discontinuation support through the new offering. The offering is targeted at the 55% of large employers that do not yet cover GLP-1s for obesity, said Sean Duffy, co-founder, CEO and director of Omada Health, during the earnings call. "...it gives these employers a structured model, where, yes, for your comments, they do pay Omada and would pay Omada more for the GLP-1 Flex Care offering because that includes clinical evaluation, prescribing lab ordering and Omada lifestyle and behavioral support while eligible employees can purchase the branded GLPs out of pocket through vetted cash pay channels, of course, with a focus on accessing the lowest available price," he said. In addition to its GLP-1 offerings, company leaders highlighted its commitment to addressing chronic disease via its cardiometabolic suite, which includes digital health programs for diabetes and hypertension, as well as its recently launched cholesterol management service. "Our ability to support obesity and weight health, diabetes, hypertension, cholesterol and MSK conditions, and GLP-1 care as 1 provider continues to be a key differentiator and the growth across our cardiometabolic suite reflects this," said Wei-Li Shao, president of Omada Health, in the earnings call. Anuja Vaidya has covered the healthcare industry since 2012. She currently covers the virtual healthcare landscape, including telehealth, remote patient monitoring and digital therapeutics. Editor's note: A previous version of this article mistakenly stated that Omada Health went public in May 2025. The article was updated on 3/6/2026.

The Associated Press
Mar 5th, 2026
Omada Health launches GLP-1 Flex Care for employers to support obesity treatment without direct medication costs

Omada Health has launched GLP-1 Flex Care, a new offering that enables employers to support obesity care whilst limiting direct medication costs. The programme provides clinical evaluation, prescribing and medical oversight, whilst members purchase GLP-1 medications independently through cash-pay channels. The solution addresses growing employee demand for GLP-1s whilst helping employers manage costs. Members receive clinical oversight, including titration management, side-effect support and nutrition counselling, alongside Omada's virtual care and coaching throughout their treatment. Research shows Omada's GLP-1 care track achieves 67% medication persistence at one year, compared to 47–49% in comparable studies, with members achieving 18.4% average weight loss versus 11.9% in real-world evidence. Omada has supported over 150,000 members on GLP-1s. The programme will be available to employers later in 2026.